AUTHORS
Jose Tinajero, PharmD, Dat Ngo, PharmD2, Tamer Othman, MD3, Vaibhav Agrawal, MD4, Paul Koller, MD5, Lindsey A. Murphy, MD, MSCS6, Yazeed Samara, MD7, Hoda Pourhassan, MD8, Amanda Blackmon, DO9, Ahmed Aribi, MD10, Julio Alvarenga Thiebaud, MD11, Rick Y. Lin, MD12, Amandeep Salhotra, MD13, Ryotaro Nakamura, MD14, Stephen J. Forman, MD15, Anthony Selwyn Stein, MD16, Guido Marcucci, MD17, Vinod Pullarkat, MD18, Ibrahim Aldoss, MD19
AFFILIATIONS
1 City of Hope National Medical Center, Duarte, California, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 City of Hope National Medical Center, Duarte, California, United States
4 City of Hope National Medical Center, Duarte, California, United States
5 City of Hope National Medical Center, Duarte, California, United States
6 City of Hope National Medical Center, Duarte, California, United States
7 City of Hope National Medical Center, Duarte, California, United States
8 City of Hope National Medical Center, Duarte, California, United States
9 City of Hope National Medical Center, Duarte, California, United States
10 City of Hope National Medical Center, Duarte, California, United States
11 City of Hope National Medical Center, Duarte, California, United States
12 City of Hope National Medical Center, Duarte, California, United States
13 City of Hope National Medical Center, Duarte, California, United States
14 City of Hope National Medical Center, Duarte, California, United States
15 City of Hope National Medical Center, Duarte, California, United States
16 City of Hope National Medical Center, Duarte, California, United States
17 City of Hope National Medical Center, Duarte, California, United States, City of Hope National Medical Center, Duarte, California, United States
18 City of Hope National Medical Center, Duarte, California, United States
19 City of Hope National Medical Center, Duarte, California, United States, City of Hope National Medical Center, Duarte, California, United States
ABSTRACT
Background: The landmark phase III E1910 trial demonstrated the benefit of incorporating blinatumomab (blina) consolidation early in the treatment course of adults with Philadelphia chromosome-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL) who achieve measurable residual disease (MRD)-negative remission, leading to its approval in this setting. However, the CALGB 10403 (C10403) regimen remains the most widely utilized pediatric-inspired regimen in young adults with ALL, and data supporting the optimal integration of blina consolidation within this framework are limited. Building upon our initial report demonstrating the safety and feasibility of incorporating blina into the C10403 (Tinajero et al., Br J Haematol, 2025), we present an expanded and updated analysis of 60 adult patients (pts) who received blina as consolidation therapy while in MRD-negative remission.
Methods
This retrospective analysis included adult pts aged 18-54 years old with newly diagnosed Ph− B-ALL who were treated consecutively with the C10403 regimen and received blina consolidation while in MRD-negative CR1 at City of Hope between February 2020 and July 2026. Our institutional practice is to administer 4 cycles of blina consolidation integrated into the C10403 regimen: 2 after consolidation, 1 after interim maintenance and 1 after delayed intensification (DI). For pts who experienced significant induction-related toxicities and achieved MRD- CR1, the first cycle of blina was administered immediately following induction. Our objectives are to report on the safety of combining blina with the CALGB 10403 regimen, and to describe early clinical outcomes including overall survival (OS), event free survival (EFS), relapse rate, asparaginase (ASNase) dose completion rates and allogeneic stem cell transplant (alloHCT) rate among pts treated with blina consolidation plus chemotherapy. Early ASNase discontinuation (D/C) was defined as 3 or less doses in pts reaching at least DI or permanent D/C and receiving 3 or less doses. OS was estimated using the Kaplan–Meier method, and its associated 95% confidence interval (CI) was calculated using the Greenwood variance estimate (RStudio, v3, Boston, MA). MRD negativity was defined as achieving <0.01% leukemic cells of total nucleated cells and was assessed by multiparameter flow cytometry
Results
Among the 60 pts who met the eligibility criteria, the median age at diagnosis was 31 years (range, 18–54), with 28.3% (n=17) aged > 40 years; 68.3% (n=41) were male. The cohort was predominantly Hispanic (86.7%, n=52) and enriched for Ph-like ALL subtype (50%, n=30). The median baseline BMI was 29 kg/m2 (range, 13–62), with 50% (n=30) of pts were obese (BMI > 30). At the time of analysis, pts had completed a median of 2 cycles (range, 1–4) of blina. Eight (13.6%) of patients received blina after induction due to prolonged hepatotoxicity (n=4), infectious complications (n=2). CRS of any grade occurred in 25% of pts (n=15), with no Grade > 3 events (0%). All-grade neuropsychiatric adverse events were reported in 16.7% (n=10), with Grade > 3 events occurring in only 3.3% (n=2) with no permanent D/C of blina. With a median follow-up of 19.8 months, the median OS was not reached (NR). The 1- and 3-year estimate for OS (95% CI) was 100% and 87.3% (76.4 – 99.8) respectively. The median EFS was not reached. The 1- and 3-year estimate for EFS (95% CI) was 94.2% (88-100) and 81.7% (69.9-95.5) respectively. There were 35% of pts (n=21) who underwent alloHCT in CR1, 76.2% (n=16) were Ph-like ALL. To date, three (5.1%) pts have relapsed, of which all had extramedullary and bone marrow involvement in addition to all retaining CD19 positivity.
Post-induction, 89.7% (n=44) completed > 50% of intended ASNase doses and 79.6% (n=39) completed > 75% of doses. ASNase was D/C after induction in 6.7% (n=4) of pts, and early D/C occurred in 25% (n=15). The most common reasons for both D/C after induction and early D/C was pancreatitis (n=3 and n=10, respectively).
Conclusions
Herein we presented an updated cohort of adult pts with B-ALL enriched with high- risk features, including Ph-like genetics, obesity, older age. In this real-world experience, integration of blina into the C10403 was feasible and safe, with low rates of high-grade toxicities and no permanent blina D/C. Notably, the majority of pts were able to receive over half of their planned ASNase doses.
DISCLOSURES
Jose Tinajero, PharmD: No relevant conflicts of interest to declare.